NCT03009266

Brief Summary

The overall aim of this study is to determine whether non-invasive imaging with myocardial contrast echocardiography using can provide information on the presence and spatial extent of recent myocardial ischemia by non-invasive echocardiographic imaging.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P50-P75 for early_phase_1

Timeline
Completed

Started Jul 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 4, 2017

Completed
1.5 years until next milestone

Study Start

First participant enrolled

July 7, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

August 23, 2018

Status Verified

August 1, 2018

Enrollment Period

1.4 years

First QC Date

December 28, 2016

Last Update Submit

August 21, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Dose optimization

    Dose ranging in normal controls to define highest dose of ultrasound contrast agent that does not produce delayed opacification from myocardial retention

    3 months

  • Detection of Ischemia

    1 year

Study Arms (2)

Normal controls

EXPERIMENTAL

Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).

Drug: Sonazoid

Patients with ACS

EXPERIMENTAL

Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.

Drug: Sonazoid

Interventions

Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid

Normal controlsPatients with ACS

Eligibility Criteria

Age19 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Normal control individuals

You may not qualify if:

  • History of cardiovascular disease (coronary artery disease, MI, peripheral artery disease)
  • allergy to eggs or ultrasound contrast agents
  • known or detected right to left shunt
  • presence of a wall motion abnormality
  • pregnancy
  • ACS GROUP
  • Patients with diagnosis of acute coronary syndrome with either unstable angina or non-ST-elevation MI
  • Referred for primary percutaneous intervention
  • At least 1 high risk features (ST changes, positive troponin, wall motion abnormality)
  • allergy to eggs or ultrasound contrast agents
  • hemodynamic instability or shock
  • known or detected right to left shunt
  • pregnancy
  • multivessel CAD requiring multivessel PCI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

OHSU

Portland, Oregon, 97239, United States

RECRUITING

Related Publications (1)

  • Davidson BP, Hodovan J, Layoun ME, Golwala H, Zahr F, Lindner JR. Echocardiographic Ischemic Memory Molecular Imaging for Point-of-Care Detection of Myocardial Ischemia. J Am Coll Cardiol. 2021 Nov 16;78(20):1990-2000. doi: 10.1016/j.jacc.2021.08.068.

MeSH Terms

Conditions

Myocardial Ischemia

Interventions

Sonazoid

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular Diseases

Central Study Contacts

Jonathan R Lindner, MD

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 28, 2016

First Posted

January 4, 2017

Study Start

July 7, 2018

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

August 23, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations